Used in pharmaceutical research as a potent and selective inhibitor of phosphoinositide 3-kinase (PI3K), specifically targeting the p110δ subunit, which plays a crucial role in immune cell signaling pathways involved in inflammation and oncogenesis. Developed for the treatment of autoimmune disorders and certain cancers, particularly hematological malignancies such as leukemia and lymphoma.

Due to its ability to inhibit B and T cell activation associated with inflammation and immune dysregulation, this compound demonstrates potential in managing chronic immune-mediated diseases, including rheumatoid arthritis and systemic lupus erythematosus (SLE).

In preclinical and research studies, it shows activity in suppressing tumor cell proliferation at the molecular level and synergizes with other chemotherapeutics to enhance efficacy, positioning it as a valuable option for combination therapies in treatment-resistant patients.

Its molecular structure confers high binding affinity and enhanced metabolic stability, making it a promising candidate for oral drug formulations. Currently in clinical development stages, with ongoing assessments of bioavailability, long-term toxicity, safety profiles, and side effects for advanced therapeutic applications.